ArticleNucleic acids research2018
ADReCS-Target: target profiles for aiding drug safety research and application.
Article in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- BEACON: predicting side effects and therapeutics outcomes to drugs by Bridging knowlEdge grAph with CONtextual language model.bioRxiv : the preprint server for biology · 2026Article
- PersADE: a database of personalized adverse drug events and their underlying molecular mechanisms.Nucleic acids research · 2026Article
- InterPAD is a database of drug-drug interaction between phytochemicals and anticancer drugs.Scientific reports · 2025Article
- Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations.Computational and structural biotechnology journal · 2025Article
- Prediction of adverse drug reactions based on pharmacogenomics combination features: a preliminary study.Frontiers in pharmacology · 2025Article
- Article
- BiMPADR: A Deep Learning Framework for Predicting Adverse Drug Reactions in New Drugs.Molecules (Basel, Switzerland) · 2024Article
- DDID: a comprehensive resource for visualization and analysis of diet-drug interactions.Briefings in bioinformatics · 2024Article
- CellSTAR: a comprehensive resource for single-cell transcriptomic annotation.Nucleic acids research · 2024Article
- DrugMAP: molecular atlas and pharma-information of all drugs.Nucleic acids research · 2023Article
- Large-scale prediction of adverse drug reactions-related proteins with network embedding.Bioinformatics (Oxford, England) · 2023Article
- The emerging role of mass spectrometry-based proteomics in drug discovery.Nature reviews. Drug discovery · 2022Review
- Network approaches for modeling the effect of drugs and diseases.Briefings in bioinformatics · 2022Review
- The heterogeneous pharmacological medical biochemical network PharMeBINet.Scientific data · 2022Article
- Prediction of Adverse Drug Reaction Linked to Protein Targets Using Network-Based Information and Machine Learning.Frontiers in bioinformatics · 2022Article
- Mining drug-target and drug-adverse drug reaction databases to identify target-adverse drug reaction relationships.Database : the journal of biological databases and curation · 2021Article
- Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease.Computational and structural biotechnology journal · 2021Article
- An omics perspective on drug target discovery platforms.Briefings in bioinformatics · 2020Article
- OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level.BMC cancer · 2020Article
- Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology.EBioMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivering safe and effective therapeutic treatment to patients is one of the grand challenges in modern medicine. However, drug safety research has been progressing slowly in recent years, compared to other fields such as biotechnologies and precision medicine, due to the mechanistic complexity of adverse drug reactions (ADRs). To fill up this gap, we develop a new database, the Adverse Drug Reaction Classification System-Target Profile (ADReCS-Target, http://bioinf.xmu.edu.cn/ADReCS-Target), which provides comprehensive information about ADRs caused by drug interaction with protein, gene and genetic variation. In total, ADReCS-Target includes 66,573 pairwise relations, among which 1710 are protein-ADR associations, 2613 are genetic variation-ADR associations, and 63,298 are gene-ADR associations. In a case study of exploring the mechanism of rash, we find that HLAs, C1QA and APOA1 are the key gene players and thus can be potential targets (or biomarkers) in monitoring or countermining rashes. In summary, ADReCS-Target can be a useful resource for the biomedical scientific community by serving researchers in the fields of drug development, clinical pharmacology, precision medicine, and from web lab to high-throughput computational platform. Particularly, it helps to identify drug with better ADR profile and design safer drug therapy regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.